SAN - Banco Santander, S.A.

NYSE - NYSE Delayed Price. Currency in USD
4.84
+0.01 (+0.21%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close4.83
Open4.82
Bid0.00 x 45900
Ask5.00 x 27000
Day's Range4.79 - 4.87
52 Week Range4.50 - 7.57
Volume4,551,176
Avg. Volume7,791,737
Market Cap77.254B
Beta (3Y Monthly)1.07
PE Ratio (TTM)10.64
EPS (TTM)0.46
Earnings DateJan 25, 2017 - Feb 1, 2017
Forward Dividend & Yield0.16 (3.27%)
Ex-Dividend Date2018-10-16
1y Target Est6.05
Trade prices are not sourced from all markets
  • GlobeNewswire2 days ago

    Sanofi: European Medicines Agency recommends fexinidazole, the first all-oral treatment for sleeping sickness

    November 16, 2018 - The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive scientific opinion of fexinidazole, the first all-oral treatment that has been shown to be efficacious for both stages of sleeping sickness. This approval is a result of clinical trials led by the non-profit research and development organization DNDi and an application submitted by Sanofi.

  • Bolsonaro Taps Santander's Campos for Brazil's Central Bank
    Bloomberg3 days ago

    Bolsonaro Taps Santander's Campos for Brazil's Central Bank

    Campos Neto, Treasury director for the Americas at Banco Santander, will replace Ilan Goldfajn, according to a text message from incoming Finance Minister Paulo Guedes. The appointment needs to be approved by Congress.

  • Hedge Funds Are Buying Banco Santander, S.A. (SAN)
    Insider Monkey4 days ago

    Hedge Funds Are Buying Banco Santander, S.A. (SAN)

    “Market volatility has picked up again over the past few weeks. Headlines highlight risks regarding interest rates, the Fed, China, house prices, auto sales, trade wars, and more. Uncertainty abounds. But doesn’t it always? I have no view on whether the recent volatility will continue for a while, or whether the market will be back […]

  • Moody's5 days ago

    GUINCHO FINANCE -- Moody's assigns provisional ratings to Guincho Finance Portuguese ABS Notes backed by NPLs to be issued by Hefesto, STC, S.A.

    Rating Action: Moody's assigns provisional ratings to Guincho Finance Portuguese ABS Notes backed by NPLs to be issued by Hefesto, STC, S.A. Moody's has not assigned any ratings to E[25,000,000] Class J Asset-Backed Variable Return Notes due [November 2038] and E[3,100,000] Class R Notes due [November 2038].

  • Bank Notes: Wells Fargo shuffles C-suite, uncovers more mortgage issues
    American City Business Journals6 days ago

    Bank Notes: Wells Fargo shuffles C-suite, uncovers more mortgage issues

    The bank said that its chief administrative officer and chief auditor have begun leaves of absence from the bank and named new leaders for key parts of the company.

  • Why Banco Santander Brasil Shares Soared 29% in October
    Motley Fool7 days ago

    Why Banco Santander Brasil Shares Soared 29% in October

    Brazilian politics provided an external boost to Santander's share price -- at least temporarily.

  • GlobeNewswire7 days ago

    Sanofi: ODYSSEY OUTCOMES investigators highlight at AHA that Praluent® (alirocumab) was associated with fewer deaths from any cause

    November 11, 2018 - New analyses on mortality from the 18,924-patient ODYSSEY OUTCOMES trial were presented at the American Heart Association (AHA) Scientific Sessions 2018. Praluent® (alirocumab) was associated with fewer deaths from any cause among patients who had previously experienced a heart attack or unstable angina (known as acute coronary syndrome, or ACS), and this was enhanced in patients who were followed for at least 3 years and those who had an LDL-C (low-density lipoprotein cholesterol) of 100 mg/dL or higher at baseline.

  • GlobeNewswire11 days ago

    New England Journal of Medicine publishes positive detailed results from Praluent® (alirocumab) cardiovascular outcomes trial

    New England Journal of Medicine publishes positive detailed results from Praluent® (alirocumab) cardiovascular outcomes trial Praluent significantly reduced major adverse.

  • Spain to Change the Law to Make Banks Pay for Stamp Duty
    Bloomberg11 days ago

    Spain to Change the Law to Make Banks Pay for Stamp Duty

    The government announcement was a response to the popular and political outrage that followed a court decision last night that home buyers should pay the tax. Prime Minister Pedro Sanchez said the government regrets the Supreme Court decision handed down late Tuesday, and that it will make banks pay the tax from the moment it publishes a decree on the matter. “Never again will Spaniards pay the tax,” Sanchez said at a news conference in Madrid on Wednesday.

  • GlobeNewswire13 days ago

    FDA grants priority review for Dupixent® (dupilumab) as potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis

    November 6, 2018 - The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) in adolescent patients 12 to 17 years of age with moderate-to-severe atopic dermatitis, whose disease was inadequately controlled with topical therapies or for whom topical treatment was medically inadvisable. Currently, there are no FDA-approved systemic biologic medicines to treat adolescents with moderate-to-severe atopic dermatitis.

  • PR Newswire13 days ago

    Santander Bank Opens First Branch in Flushing Neighborhood of Queens

    BOSTON, Nov. 5, 2018 /PRNewswire/ -- Santander Bank today announced the opening of its first branch in the Flushing neighborhood of Queens, located on 136-11 Roosevelt Avenue. To commemorate the event, Santander leaders will join community partners at a grand opening celebration and ribbon cutting later today to officially open the branch. Santander will present checks totaling $52,000 to three community organizations – Renaissance Economic Development Corporation (REDC), Chinese American Planning and Flushing Development Center.

  • Santander Successfully Launches Santander® Enterprise Payment Link
    PR Newswire13 days ago

    Santander Successfully Launches Santander® Enterprise Payment Link

    New Platform to Help Businesses Simplify and Digitize Payment Processing BOSTON , Nov. 5, 2018 /PRNewswire/ -- Santander Bank today unveiled Santander® Enterprise Payment Link (EPL), a robust, host-to-host ...

  • The Wall Street Journal18 days ago

    [$$] Turkey Doesn't Have to Be a Disaster for Banks

    Bank investors seem to be spooked by Turkey, but they may be overreacting. That is one lesson you could draw from the share-price reactions to third-quarter results from two Spanish banks.

  • GlobeNewswire18 days ago

    Sanofi and Denali Therapeutics to develop treatments for neurological and inflammatory diseases

    November 1, 2018 - Sanofi plans to collaborate with Denali Therapeutics Inc. on the development of multiple molecules with the potential to treat a range of neurological and systemic inflammatory diseases. The two lead molecules (DNL747 and DNL758) target a critical signaling protein known as the receptor-interacting serine/threonine-protein kinase 1 (RIPK1) in the TNF receptor pathway, which regulates inflammation and cell death in tissues throughout the body.

  • Associated Press18 days ago

    Banco Santander: 3Q Earnings Snapshot

    The bank, based in Madrid, said it had earnings of 13 cents per share. The financial holding company posted revenue of $13.63 billion in the period. Its revenue net of interest expense was $13.63 billion, ...

  • Reuters18 days ago

    Shares in Santander Brasil drop as bank posted lower margin

    Shares of Banco Santander Brasil SA were down 6 percent in Wednesday afternoon trading after analysts said the bank's quarterly results showed some signs of weakness in the third-quarter in spite of a higher-than-expected profit. Fee income and net interest margin - the difference between what a bank pays to borrow money and what it charges customers for loans - dropped in the quarter, raising questions if this performance would be a trend for the coming quarters. Chief Financial Officer Angel Santodomingo added fuel to the fire, saying on Wednesday that competition would pressure the bank's net income margin over coming quarters.

  • Reuters18 days ago

    Relief bounce for European shares as earnings reassure

    By Helen Reid LONDON (Reuters) - European shares rallied on Wednesday as a tumultuous October drew to a close and strong results from L'Oreal, Sanofi and banks Standard Chartered and Santander soothed ...

  • Reuters18 days ago

    UPDATE 1-Santander Brasil beats profit estimate on loan book growth

    Banco Santander Brasil SA beat analysts' third-quarter estimates for profit on Wednesday as the bank reported another quarter of strong loan book growth. Recurring net income at the Brazilian unit of Spain's Banco Santander SA (SAN .MC) came in at 3.108 billion reais ($841 million) in the third quarter, 2.85 percent above the Refinitiv average estimate from analysts and 20.2 percent above the same period a year earlier. The bank's loan book reached 380.7 billion reais, driven by individuals and small companies.

  • Benzinga18 days ago

    Jim Cramer Shares His Thoughts On Boyd Gaming, Square And More

    On CNBC's "Mad Money Lightning Round" , Jim Cramer said Seagate Technology PLC (NASDAQ: STX ) is cheap. He can see it trading higher, but he can't recommend it because there are other tech stocks ...

  • Santander draws on Spanish home comforts, capital improves
    Reuters18 days ago

    Santander draws on Spanish home comforts, capital improves

    A strong performance in its Spanish domestic market and a solid underlying business in Brazil drove Banco Santander (SAN.MC) third-quarter net profit up 36 percent from a year earlier while the lender also managed to improve its solvency position. Shares in Santander, the euro zone's biggest bank by market value, rose 4 percent on Wednesday, against a 1.5 percent rise on the European STOXX banking index (.SX7P). Analysts welcomed the bank's results at home in Spain and solid underlying performing in Brazil, as well as a recovery in Britain and its capacity to improve its capital ratios.

  • Simply Wall St.19 days ago

    Does Banco Santander SA’s (BME:SAN) P/E Ratio Signal A Buying Opportunity?

    This article is written for those who want to get better at using price to earnings ratios (P/E ratios). To keep it practical, we’ll show how Banco Santander SA’s (BME:SAN) Read More...

  • Santander Meets Capital Goal Amid Surge in Quarterly Profit
    Bloomberg19 days ago

    Santander Meets Capital Goal Amid Surge in Quarterly Profit

    Key HighlightsA positive surprise was the building of capital with 31 basis points added to fully-loaded core equity Tier 1 in the quarter, taking the measure to 11.11 percent. The election of Jair Bolsonaro has raised hopes he’ll implement reforms that will boost Santander’s largest market, and the real has recently pared losses.The U.K. showed signs of stabilizing after a tough regulatory environment and uncertainty surrounding Brexit weighed on the business in prior quarters. Santander has had to invest money in projects such as ring-fencing, which obliges banks to separate investment arms from retail banking.

  • GlobeNewswire19 days ago

    Sanofi Q3 2018 Performance Confirms Return to Growth

    Paris, October  31, 2018 Sanofi Q3 2018 Performance Confirms Return to Growth   Q3 2018 Change Change at CER 9M 2018 Change.

  • The Wall Street Journal19 days ago

    [$$] Santander Profit Surges

    Banco Santander SA’s (SAN.MC) third-quarter net profit grew strongly from a year earlier, when it reported a number of one-off charges. Net profit for the period rose roughly 36% to 1.99 billion euros ($2.